Reality Check on Non-Small Cell Lung Cancer Systemic Therapy
Market access for Non-small cell lung cancer systemic therapy treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 39% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In February 2021, the FDA gave an additional indication to Libtayo for the first-line treatment of people with advanced NSCLC whose tumors have high PD-L1 expression of tumor proportion score ≥ 50%, as determined by an FDA-approved test
- Key Findings: There are multiple drugs on the market today that are FDA approved for the treatment of non-small cell lung cancer not otherwise specified as having a targeted mutation, and more than 10 are in Phase III trials
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.